The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Summary
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global. As the COVID-19 is an emerging infectious disease, it has not scientifically recognized and has no effective drugs for treatment currently. Therefore, we will launch a scientific project "The efficacy and safety of carrimycin treatment in 520 patients with COVID-19 stratificated clinically: A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression. The primary efficiency outcomes were:(1) Fever to normal time (day); (2) Pulmonary inflammation resolution time (HRCT) (day); and (3)Negative conversion (%) of SARS-CoV-2 RNA at the end of treatment. The secondary efficiency outcomes and adverse events were observed.
Timeline
- Start
- 2020-02-23
- Primary completion
- 2021-02-28
- Completion
- 2021-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carrimycin | Unknown | — | — |
| Comparator | Chloroquine | Small molecule | — | — |
| Comparator | Lopinavir | Other / unclassified | — | — |
| Comparator | Ritonavir | Other / unclassified | — | — |
| Comparator | Umifenovir | Small molecule | — | — |